Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Monday, August 19, 2024
Clearmind Medicine Inc., a biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics for addressing significant unmet health needs, announced today the submission of a patent application under the international Patent Cooperation Treaty (PCT). This submission is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"), pursuant to an exclusive licensing agreement.
The patent application focuses on Generation 3.0 psychedelic compounds, including their methods of preparation and potential uses in treating mental disorders. These compounds were developed by Prof. Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem.
The PCT submission will enable Clearmind to advance to the national phase, where applications will be submitted to regional offices in key jurisdictions such as the US, Europe, China, and India to secure patent protection.
Dr. Adi Zuloff-Shani, CEO of Clearmind, stated, "This patent submission, if approved, will solidify the intellectual property rights for this crucial innovation under our exclusive global license agreement with Yissum. We firmly believe in the potential of psychedelic treatments as a transformative approach to addressing mental disorders, and we see Clearmind as a pioneering force in this field. The next-generation psychedelic compounds, with their advanced molecular structures, may offer a promising therapeutic option to enhance the quality of life for patients suffering from mental disorders."
Source: globenewswire.com
